From: Cancer nanomedicine: a review of recent success in drug delivery
Year | Name | Type of nano-particle | Active drug | Phase of trial | Size (nm) | Type of cancer | References |
---|---|---|---|---|---|---|---|
2017 | NU-0129 | Gold | Gold and siRNAs | I | * | Glioblastoma multiforme | [89, 90] |
2017 | MM-398 | Liposome | Irinotecan | I, II, III | 80–140 | Small cell lung cancer, metastatic pancreatic adenocarcinoma, pediatric solid tumors | [70, 88, 91, 92] |
2016* | Genexol-PM | Polymer | Paclitaxel | I/II | < 50 | Gynecologic cancer, hepatocellular carcinoma, advanced breast cancer, non-small cell lung cancer | [93,94,95,96] |
2016 | CRLX101 | Polymer | Camptothecin | I/II | 30–40 | Ovarian, rectal, renal, fallopian tube, lung (small cell and non-small cell) primary peritoneal, stomach, gastroesophageal, and esophageal cancers | [71, 72, 89, 97,98,99,100,101, 127] |
2016 | AuroLase | Silica-Gold | Gold | I | 150 | Prostate, head and neck, lung | [73, 102, 103] |
2016 | Vincristine sulfate liposome injection | Liposome | Vincristine | I/II | ~ 100 | Kaposiform hemangioendotheloma, Kasabach–Merritt Syndrome, tufted angioma, rhabdomyosarcoma, recurrent adult acute myeloid leukemia, lymphoblastic leukemia***, multiple lymphomas (non-hodgkin, follicular, mantle-cell, small-cell, and B-cell [Margional Zone]), Waldenstrom macroglobulinemia | [87, 104,105,106,107,108] |
2016 | Anti-EGFR immuno-liposome | Liposome | Doxorubicin | II | 130–200 | Breast cancer | [74, 109, 110] |
2015 | Mitoxantrone HCl liposome injection (plm60-s) | Liposome | Mitoxantrone | II | 60 | Breast cancer, diffuse large B-cell lymphoma, non-Hodgkin’s lymphoma, and peripheral T/NK lymphomas | [75, 111,112,113,114] |
2014 | CPX-351 | Liposome | I | * | Acute myeloid leukemia | [115] | |
2014 | LipoCURC | Liposome | Curcumin | I/II | * | Advanced cancer with failed standard of care therapy | [116] |
2014 | SGT-53 | Liposome | Plasmid containing normal human wild type p53 DNA | I/II | * | Glioblastoma, neoplasm, metastatic pancreatic cancer | [117,118,119,120] |
2013 | LiPlaCis | Liposome | Cisplatin | I/II | * | Advanced or refractory solid tumours, metastatic breast cancer | [121, 122] |
2012 | PROMITIL | Liposome | Mitomycin-C | I | ~ 90 | Solid tumors | [123, 124] |
2011 | Abraxane | Protein-drug conjugate | Paclitaxel | II | ~ 130 | Breast cancer** | [125] |